| In 000€ | Materialise
Medical |
Materialise
Software |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||
| For the three months ended June 30, 2024 | ||||||||||||
| Revenues | 28,141 |
11,226 |
29,429 |
68,797 |
0 |
68,797 |
||||||
| Segment (adj) EBITDA | 8,199 |
1,374 |
2,416 |
11,990 |
(2,802) |
9,188 |
||||||
| Segment (adj) EBITDA % | 29.1% |
12.2% |
8.2% |
17.4% |
13.4% |
|||||||
| For the three months ended June 30, 2023 | ||||||||||||
| Revenues | 24,945 |
11,030 |
28,835 |
64,810 |
0 |
64,810 |
||||||
| Segment (adj) EBITDA | 2,683 |
1,973 |
2,708 |
7,364 |
(2,608) |
4,755 |
||||||
| Segment (adj) EBITDA % | 10.8% |
17.9% |
9.4% |
11.4% |
7.3% |
|||||||
| In 000€ | Materialise
Medical |
Materialise
Software |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||
| For the six months ended June 30, 2024 | ||||||||||||
| Revenues | 54,324 |
21,665 |
56,445 |
132,434 |
0 |
132,434 |
||||||
| Segment (adj) EBITDA | 16,120 |
2,464 |
3,947 |
22,531 |
(5,248) |
17,283 |
||||||
| Segment (adj) EBITDA % | 29.7% |
11.4% |
7.0% |
17.0% |
13.1% |
|||||||
| For the six months ended June 30, 2023 | ||||||||||||
| Revenues | 49,265 |
22,381 |
59,056 |
130,702 |
0 |
130,702 |
||||||
| Segment (adj) EBITDA | 10,035 |
4,409 |
5,906 |
20,350 |
(5,285) |
15,066 |
||||||
| Segment (adj) EBITDA % | 20.4% |
19.7% |
10.0% |
15.6% |
11.5% |
|||||||
| (1) Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. | ||||||||||||
Materialise Reports Second Quarter 2024 Results
 |  | More MCAD News
|
|
Segment P&L (Unaudited)
RELATED NEWS
